So far, the total (placebo group + two treatment groups) have 70% reduction at 12 weeks. Assume placebo group achieves 55% reduction at 12 weeks, as per graph. Assume also that both treatment groups have same wound reduction. Simple algebra shows that reduction to be 77%. Thus the treatment over standard care delivers 22% greater wound reduction - much better than "pretty effective".
The study design has primary endpoint efficacy success at 10% greater reduction for treatment over standard care (i.e., ~70% VF001 and ~60% placebo). But so far it looks like it might achieve 22%. So, even before the results are unblinded there is a very strong indication that this will be a success.
- Forums
- ASX - By Stock
- Ann: Investor Presentation
So far, the total (placebo group + two treatment groups) have...
-
- There are more pages in this discussion • 24 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add DLM (ASX) to my watchlist
(20min delay)
|
|||||
Last
3.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $7.227M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
DLM (ASX) Chart |
Day chart unavailable
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non--Executive Director
Simon Kidston
Non--Executive Director
SPONSORED BY The Market Online